DUBLIN, Mar. 6, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report" report to their offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million.
The report profiles 23 companies including many key and niche players such as
- AstraZeneca Plc. (UK)
- Bayer HealthCare Pharmaceuticals (Germany)
- Bristol-Myers Squibb Company (US)
- Merck & Co., Inc. (US)
- Proteon Therapeutics, Inc. (US)
- Sanofi S.A. (France)
- Symic Bio, Inc. (US)
- TheraVasc Inc. (US)
Key Topics Covered:
1. INDUSTRY OVERVIEW
- A Prelude
- PAD Statistics
- Critical Limb Ischemia
- An Insight
- High Costs
- A Cause of Concern
2. PAD THERAPEUTICS
- Anti-Platelet Drugs: Spearheading the Battle against PAD
- Key Drugs for Arterial Disease
- Clopidogrel (Plavix)
- Prasugrel (Effient)
- Ticagrelor (Brilinta)
- Vorapaxar (Zontivity)
- Dual Antiplatelet Therapy (DAPT) for PAD
- Entry of Generics Tones Down Growth in Major Markets
- Brilinta Fails to Meet Expectations in EUCLID Trial
- Xarelto Pins Hope on COMPASS and VOYAGER trials
- Other Pipeline Drugs for Peripheral Arterial Disease (PAD)
- Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal
3. MACRO GROWTH DRIVERS
- Aging
- A Key Driver
- High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics
4. PERIPHERAL ARTERIAL DISEASE (PAD) - AN OVERVIEW
- Peripheral Arterial Disease: Understanding the Stealthy Peril
- Causes of PAD
- Tobacco Use
- Diabetes
- Dyslipidemia
- Hypertension
- Causes of PAD in Lower Extremities
- Atherosclerosis
- Blood Clotting
- Link Established between Depression and PAD
- Ethyl-EPA Intake Proves Favorable for PAD Sufferers
- PAD Risk Factors
- Symptoms of PAD
- Claudication
- Rest Pain
- Other Symptoms
- Prognosis of PAD
- Diagnosis of PAD
- Ankle Brachial Index (ABI)
- Ankle-Brachial Index and Associated Severity of Peripheral Arterial Disease
- Magnetic Resonance Angiography (MRA) and CT Scan
- Control of PAD
- Classification of PAD Severity
- Methods for Avoiding PAD Complications
- Treatment Options for Peripheral Arterial Disease
- A General Perspective
- Lifestyle Changes
5. COMPANIES INTO GENE THERAPY FOR PAD
- AnGes MG, Inc. (Japan)
- Athersys, Inc. (US)
- Betagenon AB (Sweden)
- CardioVascular BioTherapeutics, Inc. (US)
- Celgene Corporation (US)
- ID Pharma Co., Ltd. (Japan)
- miRagen Therapeutics, Inc. (US)
- Multi Gene Vascular Systems Ltd (Israel)
- ViroMed Co. Ltd. (Korea)
6. CLINICAL STUDIES/CORPORATE INITIATIVES
- AstraZeneca Announces Results of EUCLID Trial
- USPTO Extends Patent Term for Bayer's Rivaroxaban
- Bayer and Janssen Expand Clinical Development Programme for Rivaroxaban
- FDA Approves Merck's Zontivity
7. FOCUS ON SELECT GLOBAL PLAYERS
8. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 23 (including Divisions/Subsidiaries 25)
- The United States (9)
- Canada (1)
- Japan (2)
- Europe (7)
- - France (1)
- - Germany (2)
- - The United Kingdom (1)
- - Rest of Europe (3)
- Asia-Pacific (Excluding Japan) (6)
For more information about this report visit http://www.researchandmarkets.com/research/jxndrb/peripheral
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
